VKTX Viking Therapeutics Inc.

5.05
+0.13  (+3%)
Previous Close 4.92
Open 4.98
Price To Book 1.32
Market Cap 366,442,458
Shares 72,562,863
Volume 1,382,449
Short Ratio
Av. Daily Volume 1,451,047
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial initiation announced November 19, 2019. Phase 2 additional data to be presented at EASL April 17, 2020.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture
Phase 1 trial to be initiated 1H 2020.
VK0214
X-linked adrenoleukodystrophy

Latest News

  1. Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference

  2. Viking Therapeutics, Inc. (FormDEFA14A) (0001564590-20-015533)

  3. Viking Therapeutics, Inc. (FormDEF 14A) (0001564590-20-015522)

  4. Viking Therapeutics, Inc. Changes to Beneficial Ownership: MORNEAU MICHAEL (VP, Finance and Administration) (Form4) (0001209191-20-023378)

  5. Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,

  6. Viking Therapeutics to Participate in Upcoming Investor Conferences

    SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  7. Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020

    SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  8. Viking Therapeutics to Present at Biotech Showcase 2020

    SAN DIEGO, Jan. 6, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  9. Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

    SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,

  10. Viking Therapeutics to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  11. Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  12. Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019

    SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  13. Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine

  14. Viking Therapeutics to Participate in Upcoming Investor Conferences

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine